The Peritoneum pp 209-230 | Cite as


  • Gere S. diZerega
  • Kathleen E. Rodgers


Fibrinolysis, which represents the end stage of coagulation, was defined by Dastre in 1893 as the dissolution of polymerized fibrin. Todd (1959) reported the presence of fibrinolytic activity in serosal cells derived from human peritoneum and pleura. Astrup and Allbrechtsen (1957) demonstrated plasminogen activator in extracts of serosa from the human fallopian tube and parietal peritoneum of the rat uterus. These studies were confirmed by others who demonstrated fibrinolytic activity and plasminogen activator in parietal pleura, pericardium, and peritoneum (Myhre-Jensen, Larsen, & Astrup, 1969; Porter, McGregor, Mullen, & Silver, 1969; Porter, Ball, & Silver, 1971; Raftery, 1979; Merlo, Fausone, Barbero, & Castagna, 1980). Pugatch and Poole (1969) subsequently reported the presence of fibrinolysis-inhibiting agents in bovine parietal peritoneum. Plasmin, the major enzyme involved in fibrinolysis, is formed from the inactive precursor, plasminogen, by the action of plasminogen activators (PA). PAs are found in urine, tissues, and blood. Normally, coagulation and fibrinolysis are in balance such that no net fibrin deposition occurs.


Plasminogen Activator Mesothelial Cell Adhesion Formation Plasminogen Activator Plasminogen Activator Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe H, Rodgers KE, Campeau JD, Girgis W, Ellefson D, diZerega GS. (1990). The effect of intraperitoneal administration of sodium tolmetin-hyaluronic acid on the postsurgical cell infiltration in vivo. J Surg Res. 49: 322–327.PubMedCrossRefGoogle Scholar
  2. Albrechtsen OK. (1956). The fibrinolytic activity of the human endometrium. Acta Endocrinol 23: 207–218.PubMedGoogle Scholar
  3. Albrechtsen OK. (1957a). The fibrinolytic activity of human tissues. Br J Haematol 3: 284–291.PubMedCrossRefGoogle Scholar
  4. Albrechtsen OK. (1957b). The fibrinolytic activity of animal tissues. Acta Physiol Scand. 39: 284–290.PubMedCrossRefGoogle Scholar
  5. Andersson L, Nilsson IM, Olow B. (1962). Fibrinolytic activity in man during surgery. Thromb Diath Haemorrh. 7: 392–403.Google Scholar
  6. Andersson L. (1964). Antifibrinolytic treatment with epsilon-amino-caproic acid in connection with prostatectomy. Acta Chir Scand. 127: 552–559.PubMedGoogle Scholar
  7. Astrup T, Albrechtsen OK. (1957). Estimation of the plasminogen activator and the trypsin inhibitor in animal and human tissues. Scand J Clin Lab Invest. 9: 233–243.PubMedCrossRefGoogle Scholar
  8. Astrup T, Albrechtsen OK, Claassen M, Rasmussen J. (1959). Thromboplastic and fibrinolytic activity of human aorta. Circ Res. 7: 969–974.PubMedGoogle Scholar
  9. Astrup T, Claassen M. (1957). Fibrinolytic activity of the peritoneum. Trans. 6th Congr. European Soc. Haematol., Copenhagen. Basel; Karger; 455–459.Google Scholar
  10. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. (1989). Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 74: 165–177.PubMedGoogle Scholar
  11. Booth NA, Anderson JA, Bennett B. (1985). Platelet release protein which inhibits plasminogen activators. J Clin Pathol. 38: 825–830.PubMedCrossRefGoogle Scholar
  12. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. (1990). Plasminogen activator inhibitor 1 and 2, α2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res. 57: 271–275.PubMedCrossRefGoogle Scholar
  13. Britton BJ, Giddings JC, Brooks L, Bloom AL. (1977). Fibrinolytic, factor VIII and pulse rate responses to repeated adrenaline infusion followed by haemorrhagia. Thromb Haemost. 37: 527–534.PubMedGoogle Scholar
  14. Buckman RF Jr., Maj MC, Buckman PD, Hufnagel HV, Gervin AS. (1976). A physiologic basis for the adhesion-free healing of deperitonealized surfaces. J Surg Res. 21: 67–76.PubMedCrossRefGoogle Scholar
  15. Chakrabarti R, Hocking ED, Fearnley GR. (1969). Reaction pattern to three stresses—electroplexy, surgery and myocardial infarction—of fibrinolysis and plasma fibrinogen. J Clin Pathol. 22: 659–662.PubMedCrossRefGoogle Scholar
  16. Chapman HA Jr, Stone OL, Vavrin Z. (1984). Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest. 73: 806–815.PubMedCrossRefGoogle Scholar
  17. Coccheri S, Astrup T. (1961). Thromboplastic and fibrinolytic activities of large human vessels. Proc Soc Exp Biol Med. 108: 369–372.PubMedGoogle Scholar
  18. Dastre A. (1893). Fibrinolyse dans le sang. Arch Physiol Norm Pathol. 5: 661–663.Google Scholar
  19. Deutsch DG, Mertz ET. (1970). Plasminogen purification from human plasma by affinity chromatography. Science. 170: 1095–1096.PubMedCrossRefGoogle Scholar
  20. Donse AM, Dupuy E, Bodevin E. (1978). Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res. 12: 377–387.CrossRefGoogle Scholar
  21. Doody KJ, Dunn RC, Buttram VC. (1989). Recombinant tissue plasminogen activator reduces adhesion formation in a rabbit uterine horn model. Fertil Steril. 51: 509–512.PubMedGoogle Scholar
  22. Ellis H, Harrison W, Hugh TB. (1965). The healing of peritoneum under normal and pathologic conditions. Br J Surg. 52: 471–476.PubMedCrossRefGoogle Scholar
  23. Emeis JJ, Van Hinsbergh VWM, Verheijen JH, Wijngaards G. (1983). Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun. 110: 392–398.PubMedCrossRefGoogle Scholar
  24. Ende N, Auditore J. (1961). Fibrinolytic activity of human tissues and dog mast cell tumors. Am J Clin Pathol 36: 16–24.PubMedGoogle Scholar
  25. Engqvist A, Winther O. (1972). Variations of plasma Cortisol and blood fibrinolytic activity during anaesthetic and surgical stress. Br J Anaesth. 44: 1291–1297.CrossRefGoogle Scholar
  26. Erickson LA, Ginsberg MH, Loskutoff DJ. (1984). Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 74: 1465–1472.PubMedCrossRefGoogle Scholar
  27. Esnard F, Dupuy E, Dosne AM, Bodevin E. (1982). Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein. Thromb Haemost. 47: 128–131.PubMedGoogle Scholar
  28. Fukasawa M, Campeau JD, Girgis W, Bryant SW, Rodgers KE, diZerega GS. (1989). Production of protease inhibitors by postsurgical macrophages. J Surg Res. 46: 256–261.PubMedCrossRefGoogle Scholar
  29. Gervin AS, Puckett CL, Silver D. (1973). Serosal hypofibrinolysis. A cause of postoperative adhesions. Am J Surg. 125: 80–88.PubMedCrossRefGoogle Scholar
  30. Grossbard EB. (1987). Recombinant tissue plasminogen activator: a brief review. Pharmacol Res. 4: 375–378.CrossRefGoogle Scholar
  31. Hau T, Payne D, Simmons RL. (1979). Fibrinolytic activity of the peritoneum during experimental peritonitis. Surg Gynecol Obstet. 148: 415–418.PubMedGoogle Scholar
  32. Hedlund PO. (1969). Antifibrinolytic therapy with cyklokapron in connection with prostatectomy. Scand J Urol Nephrol. 3: 177–182.PubMedCrossRefGoogle Scholar
  33. Innes D, Sevitt S. (1974). Coagulation and fibrinolysis in injured patients. J Clin Pathol. 17: 1–13.CrossRefGoogle Scholar
  34. Jespersen J, Astrup TA. (1983). Study of the fibrin plate assay of fibrinolytic agents. Haemostasis. 13: 301–315.PubMedGoogle Scholar
  35. Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. (1973). Blood coagulation and fibrinolysis in relation to degree of physical activity during work and leisure time. Acta Med Scand. 193: 73–77.PubMedCrossRefGoogle Scholar
  36. Kruithof EKO, Tran-Thang C, Ransijn A, Backmann F. (1984). Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood. 64: 907–913.PubMedGoogle Scholar
  37. Laug WE. (1985). Vascular smooth muscle cells inhibit plasminogen activator secreted by endothelial cells. Thromb Haemost. 53: 165–169.PubMedGoogle Scholar
  38. Levin EG. (1983). Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA. 80: 6804–6808.PubMedCrossRefGoogle Scholar
  39. Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. (1983). Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA. 80: 2956–2961.PubMedCrossRefGoogle Scholar
  40. Macfarlane RG. (1937). Fibrinolysis following operation. Lancet. 1: 10.CrossRefGoogle Scholar
  41. Markwardt F, Klocking HP. (1977). Heparin-induced release of plasminogen activator. Haemostasis. 6: 370–374.PubMedGoogle Scholar
  42. Mayer M, Yedgar S, Hurwitz A, Palti Z, Finzi Z, Milwidsky A. (1988). Effect of viscous macromolecules on peritoneal plasminogen activator activity: potential mechanism for their ability to reduce postoperative adhesion formation. Am J Obstet Gynecol. 159: 957–963.PubMedGoogle Scholar
  43. Menzies D, Ellis H. (1989). Intra-abdominal adhesions and their prevention by topical tissue plasminogen activator. J R Soc Med. 82: 534–535.PubMedGoogle Scholar
  44. Merlo G, Fausone G, Barbero C, Castagna B. (1980). Fibrinolytic activity of the human peritoneum. Eur Surg Res. 12: 433–438.PubMedCrossRefGoogle Scholar
  45. Moroz LA, Gilmore NJ. (1976). Fibrinolysis in normal plasma and blood: evidence for significant mechanisms independent of the plasminogen-plasmin system. Blood. 48: 531–545.PubMedGoogle Scholar
  46. Myhre-Jensen O, Larsen SB, Astrup T. (1969). Fibrinolytic activity in serosal and synovial membranes. Arch Pathol. 88: 623–630.Google Scholar
  47. Nilsson IM, Pandolfi M. (1970). Fibrinolytic response of the vascular wall. Thromb Diath Haemorrh Suppl. 40: 231–242.Google Scholar
  48. Ny T, Bjersing L, Hsuek AJW, Loskutoff DJ. (1985). Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology. 116: 1666–1668.PubMedCrossRefGoogle Scholar
  49. Orita H, Girgis W, diZerega GS. (1991). Inhibition of postsurgical adhesions in a standardized rabbit model: intraperitoneal administration of tissue plasminogen activator. Int J Fert. 36: 172–177.Google Scholar
  50. Philips M, Juul AG, Thorsen S. (1984). Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta. 802: 99–110.PubMedGoogle Scholar
  51. Pike GJ, Turner RL, Manohitharajah SM, Deverall PB. (1975). Fibrinolysis in cyanotic and acyanotic children before and after open intracardiac operations with the Bentley temptrol oxygenator. J Thorac Cardivosc. Surg. 69: 922–926.Google Scholar
  52. Porter JM, McGregor FH, Mullen DC, Silver D. (1969). Fibrinolytic activity of mesothelial surfaces. Surg Forum. 20: 80–82.PubMedGoogle Scholar
  53. Porter JM, Ball AP, Silver D. (1971). Mesothelial fibrinolysis. J Thorac Cardiovasc Surg. 62: 725–730.PubMedGoogle Scholar
  54. Pugatch EM, Poole JC. (1969). Inhibitor of fibrinolysis from mesothelium. Nature. 221: 269–270.PubMedCrossRefGoogle Scholar
  55. Raftery AT. (1979). Regeneration of peritoneum: a fibrinolytic study. J Anat. 129: 659–664.PubMedGoogle Scholar
  56. Raftery AT. (1981a). Effect of peritoneal trauma on peritoneal fibrinolytic activity and intraperitoneal adhesion formation. Eur Surg Res. 13: 397–401.PubMedCrossRefGoogle Scholar
  57. Raftery AT. (1981b). A method for measuring fibrinolytic activity in a single layer of cells. J Clin Pathol. 34: 625–629.PubMedCrossRefGoogle Scholar
  58. Ratnoff OD. (1953). Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrated for the proteolytic enzyme of plasma. J Clin Invest. 32: 473–479.PubMedCrossRefGoogle Scholar
  59. Rennie JAN, Bennett B, Ogston D. (1977). Effect of local exercise and vessel occlusion on fibrinolytic activity. J Clin Pathol. 30: 350–352.PubMedCrossRefGoogle Scholar
  60. Rodgers KE. (1990). Nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of postsurgical adhesion. In: diZerega GS, Malinak LR, Diamond MD, Linsky CL, eds. Treatment of Postsurgical Adhesions (Progress in Clin Biol Res). New York: Wiley-Liss Press; 358: 119–130.Google Scholar
  61. Rodgers KE, Abe H, Campeau JD, Ellefson DD, Girgis W, diZerega GS. (in press). In vivo administration of tolmetin in hyaluronic acid modulates protease secretion by postsurgical macrophages. J Invest Surg.Google Scholar
  62. Ryan GB, Grobety J, Majno G. (1973). Mesothelial injury and recovery. Am J Pathol. 71: 93–112.PubMedGoogle Scholar
  63. Silverman P, Goldsmith GH Jr., Spitzer TR, Rehmus EH, Berger NA. (1990). Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncol. 8: 468–472.PubMedGoogle Scholar
  64. Sprengers ED, Verheijen JH, Van Hinsbergh VWM, Emeis JJ. (1984). Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta. 801: 163–170.PubMedGoogle Scholar
  65. Thorsen S, Philips M. (1984). Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta. 802: 111–118.PubMedGoogle Scholar
  66. Todd AS. (1958). Fibrinolysis autographs. Nature. 181: 495–496.PubMedCrossRefGoogle Scholar
  67. Todd AS. (1959). The histological localisation of fibrinolysis activator. J Pathol Bacteriol. 78: 281–283.PubMedCrossRefGoogle Scholar
  68. Unkeless JC, Gordon S, Reich S. (1974). Secretion of plasminogen activator by stimulated macrophages. J Exp Med. 139: 834–850.PubMedCrossRefGoogle Scholar
  69. van der Poll T, Levi M, Buller HR, van Deventer SJA, de Boer JP, Hack CE, ten Cate JW. (1991). Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 175: 729–732.Google Scholar
  70. van Hinsbergh VWM, Kooistra T, Scheffer MA, van Bockel JH, van Muijen GNP. (1990). Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood. 75:1490–1497.PubMedGoogle Scholar
  71. Vipond MN, Whawell SA, Thompson JN, Dudley HAF. (1990). Peritoneal fi-brinolytic activity and intra-abdominal adhesions. Lancet. 335: 1120–1122.PubMedCrossRefGoogle Scholar
  72. Wallenbeck IAM, Tangen O. (1975). On the lysis of fibrin formed in the presence of dextran and other macromolecules. Thromb Res. 6: 75–86.PubMedCrossRefGoogle Scholar
  73. Whitaker D, Papadimitriou JM, Walters N-I. (1982). The mesothelium: its fibrinolytic properties. J Pathol. 136: 295–299.Google Scholar

Copyright information

© Springer-Verlag Berlin New York, Inc. 1992

Authors and Affiliations

  • Gere S. diZerega
    • 1
  • Kathleen E. Rodgers
    • 1
  1. 1.School of Medicine Livingston Research CenterUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations